Obtain the Pulse from the Market with StreetInsider.com’s Pulse Picks. Get the Free Trial Offer here.


Further data will be provided later on guides and medical conferences.

“We are happy to announce good results within this Phase 3 trial of Epidiolex in patients with Lennox-Gastaut syndrome, especially pleased this outcome is in line with our recent Phase 3 pivotal data for Epidiolex in Dravet syndrome. We feel this result further shows that Epidiolex provides the potential to become a new effective therapy within the concept of treatment-resistant childhood-onset epilepsies,” mentioned Justin Gover, GW’s Ceo. “We now anticipate evolving Epidiolex for the submission of the NDA using the Food and drug administration within the first 1 / 2 of 2017.”

Trial Overview and Result

Patients aged 2-55 years having a confirmed proper diagnosis of drug-resistant LGS presently out of control on a number of concomitant anti-epileptic drugs (AEDs) were qualified to sign up within this Phase 3, randomized, double-blind placebo-controlled trial. The trial randomized 171 patients into two arms, where Epidiolex 20mg/kg/day (n=86) or placebo (n=85) was put into current AED treatment. Typically, patients had to have roughly 3 AEDs, getting formerly attempted and unsuccessful typically 6 other AEDs. The typical chronilogical age of trial participants was fifteen years (34% were 18 years or older). The median baseline drop seizure frequency monthly was 74.

About Lennox-Gastaut Syndrome

The height start of LGS typically happens between day of three to five years and could be caused by a few conditions, including brain malformations, severe mind injuries, nervous system infections, and inherited degenerative or metabolic conditions. In as much as 30 % of patients, no cause are available. Patients with LGS generally have multiple seizure types including non-convulsive, convulsive and drop seizures, which regularly result in falls and injuries. Drug resistance is among the primary options that come with LGS. Most kids with LGS experience some extent of impaired intellectual functioning, in addition to developmental delays and behavior disturbances. It’s believed there are roughly 14,000-18,500 patients with LGS within the U . s . States and 23,000-31,000 patients with LGS in Europe.

GW has commenced a Phase 3 trial of Epidiolex in Tuberous Sclerosis Complex and wants to initiate a Phase 3 trial of Epidiolex in infantile spasms within the 4th quarter of the year.

Investor Business Call and Webcast Information

Additionally for this first Phase 3 trial of Epidiolex in LGS, GW is performing another Phase 3 dose-varying trial of Epidiolex to treat LGS, that is fully enrolled at 225 patients. This second trial has three treatment arms: Epidiolex 20mg/kg/day, 10mg/kg/day and placebo. GW wants to report top-line is a result of this trial for the finish from the third quarter of the year.

GW Medical Trial Programs in Dravet Syndrome, Tuberous Sclerosis Complex and Infantile Spasms

References: LGS Foundation: http://world wide web.lgsfoundation.orgEpilepsia. 2014 Sep55 Suppl 4:4-9. doi: 10.1111/epi.12567., Lennox-Gastaut syndrome: a consensus method of differential diagnosis., Bourgeois BF1, Douglass LM, Sankar R.

About GW Pharmaceutical drugs plcFounded in 1998, GW is really a biopharmaceutical company centered on finding, developing and commercializing novel therapeutics from the proprietary cannabinoid product platform inside a wide range of disease areas. GW is evolving an orphan drug program in the area of childhood-onset epilepsy having a concentrate on Epidiolex® (cannabidiol), that is in Phase 3 clinical development to treat Dravet syndrome, LGS and Tuberous Sclerosis Complex. GW effectively developed the world’s first plant-derived cannabinoid prescription medication, Sativex®, that is approved to treat spasticity because of ms in 28 nations outdoors the U . s . States. GW includes a deep pipeline of more cannabinoid product candidates including compounds in Phase 1 and a pair of tests for glioma, schizophrenia and epilepsy. For more information, check out world wide web.gwpharm.com.

GW Pharmaceutical drugs will host a celebration call and webcast for analysts and traders to go over the outcomes out of this early on 3 trial today at 8:00 a.m. EDT /13:00 BST. To have fun playing the business call, please dial 877-407-8133 (toll-free in the U.S. and Canada), or 0800-756-3429 (toll-free in the United kingdom) or 201-689-8040 (worldwide). Traders might also access an active audio webcast from the call through the investor relations portion of the Company’s website at http://world wide web.gwpharm.com. A replay from the call may also be available with the GW website soon after the phone call and can remain readily available for 3 months. Replay Figures: (toll-free): 1-877-660-6853, (worldwide): 1-201-612-7415. For dial-in figures please use conference ID # 13639965.

“Lennox-Gastaut syndrome is really a hard type of epilepsy to deal with. Additional effective and safe remedies are anxiously required for patients who still have a problem with out of control seizures,” stated Christina SanInocencio, Executive Director from the Lennox-Gastaut Syndrome Foundation. “We are thrilled using these good results, that offer necessary hope and promise to individuals coping with this debilitating condition.”

About EpidiolexEpidiolex, GW’s lead cannabinoid product candidate, is definitely an dental pharmaceutical formulation of pure CBD, that is in development to treat numerous rare childhood-onset epilepsy disorders. GW has carried out extensive pre-clinical research of CBD in epilepsy since 2007. These studies has proven that CBD has significant anti-epileptiform and anticonvulsant activity using a number of in vitro and in vivo models and reduced seizures in a variety of acute animal types of epilepsy. Up to now, GW has gotten Orphan Drug Designation in the Food and drug administration for Epidiolex to treat Dravet syndrome, LGS, Tuberous Sclerosis Complex and infantile spasms. Furthermore, GW has gotten Steps For Success Designation in the Food and drug administration and Orphan Designation in the European Medications Agency for Epidiolex to treat Dravet syndrome. GW is presently evaluating additional clinical development programs in other orphan seizure disorders.

The main effectiveness endpoint of the trial would be a comparison between Epidiolex and placebo within the percentage alternation in the monthly frequency of drop seizures throughout the 14 week treatment period (2 week dose escalation period adopted by 12 days of maintenance) in comparison towards the 4 week baseline period before randomization. Drop seizures were understood to be atonic, tonic and tonic-clonic seizures concerning the human body, trunk or mind that brought or might have brought to some fall, injuries, slumping inside a chair or striking the patient’s mind on the surface. Throughout the treatment period, patients taking Epidiolex accomplished an average decrease in monthly drop seizures of 44 % in comparison having a decrease in 22 percent in patients receiving placebo, and also the distinction between remedies was statistically significant (p=.0135).

Contacts:

In March 2016, GW introduced good results from the first pivotal Phase 3 trial of Epidiolex in Dravet syndrome. GW is constantly on the enroll another Phase 3 trial of Epidiolex in Dravet syndrome.

Source: GW Pharmaceutical drugs plc

“From a physician’s perspective, the positive outcome within this trial of Epidiolex in patients with Lennox-Gastaut syndrome is extremely exciting. Lennox-Gastaut syndrome starts when they are young, is especially hard to treat, and most patients don’t get the sufficient response from existing treatments,” mentioned Linda Laux, MD, Director from the Comprehensive Epilepsy Center at Ann &amplifier Robert H. Lurie Children’s Hospital of Chicago and assistant professor of pediatric medicine, Northwestern College Feinberg Med school as well as an investigator within the trial. “These data reveal that Epidiolex can give a robust and scientifically significant decrease in seizures within this highly treatment-resistant population along with a suitable safety and tolerability profile, that is in line with these clinical knowledge about Epidiolex. I’m looking forward to the possibilities of Epidiolex being provided on prescription later on and accept is as true can make an essential impact on the lives of numerous patients.”

GW Pharmaceutical drugs plc (Nasdaq: GWPH) announces good results from the first randomized, double-blind, placebo-controlled Phase 3 medical trial of their investigational medicine Epidiolex (cannabidiol or CBD) to treat Lennox-Gastaut syndrome (LGS), an uncommon and severe type of childhood-onset epilepsy. Within this trial, Epidiolex, when added being an adjunct towards the patient’s current treatment, accomplished the main endpoint of the significant decrease in the monthly frequency of drop seizures assessed within the entire 14-week treatment period in comparison with placebo (p=.0135). This trial follows the announcement in March 2016 of positive produces a pivotal Phase 3 trial of Epidiolex to treat Dravet syndrome. Epidiolex has Orphan Drug Designation in the U.S. Fda (Food and drug administration) to treat LGS and Dravet syndrome.

Forward-searching claimsWhat is the news release could have forward-searching claims that reflect GWs current anticipations regarding future occasions, including claims concerning the therapeutic benefit, safety profile and commercial worth of the business’s investigational drug Epidiolex, the expansion and commercialization of Epidiolex, plans and objectives for product, plans and objectives for present and future clinical tests and outcomes of such tests, plans and objectives for regulating submissions and approvals. Forward-searching claims involve risks and uncertainties. Actual occasions could differ materially from individuals forecasted herein and rely on numerous factors, including (inter alia), the prosperity of the GW’s research methods, the usefulness from the breakthroughs made within, the effective and timely completing uncertainties associated with the regulating process, and also the acceptance of Sativex, Epidiolex, if approved, along with other items which we might commercialize by consumer and doctors. An additional list and outline of risks, uncertainties along with other risks connected by having an purchase of GW are available in GW’s filings using the U.S. Investments and Exchange Commission. Existing and prospective traders are cautioned to not place undue reliance upon these forward-searching claims, which speak only by the date hereof. GW undertakes no obligation to update or revise the data found in this pr release, whether because of new information, future occasions or conditions or else.

A number of sensitivity analyses from the primary endpoint confirmed the sturdiness of the result. The main difference between Epidiolex and placebo emerged throughout the first month of treatment and it was sustained over the treatment period. Is a result of secondary effectiveness endpoints strengthened the general effectiveness observed with Epidiolex.

GW Pharmaceutical drugs plc
Stephen Schultz, VP Investor Relations (U.S.) 401 500 6570
FTI Talking to (United kingdom Media)
Ben Atwell / Simon Conway + 44 20 3727 1000
FleishmanHillard (U.S. Media)
Paddi Hurley / Adam Silverstein 212 453 2382 / 212 453 2493

Epidiolex was generally well tolerated within this trial. Overall, 86 percent of Epidiolex patients experienced a bad event in comparison with 69 percent of patients on placebo. The most typical adverse occasions (occurring in more than 10 % of Epidiolex-treated patients) were: diarrhea, somnolence, decreased appetite, pyrexia, and vomiting. Of individuals patients on Epidiolex who reported a bad event, 78 percent reported so that it is mild or moderate. Twenty patients on Epidiolex possessed a serious adverse event (nine which were considered treatment related) in comparison with four patients on placebo (one of these was considered treatment related). Twelve patients on Epidiolex stopped treatment because of adverse occasions in comparison with one patient on placebo. There is one dying within the Epidiolex group, that was considered unrelated to treatment. Of the sufferers who completed this trial, 100 % have opted to carry on into a wide open-label extension trial.

Leave a Comment

Your email address will not be published. Required fields are marked *